Prof. Dr. Tuğçe Nur YİĞENOĞLU

1. Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial

Broome C. M., Miyakawa Y., McDonald V., Al-Samkari H., Khelif A., Cataland S. R., et al.

American Journal of Hematology , cilt.101, sa.7, ss.1494-1506, 2026 (SCI-Expanded, Scopus)

2. Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin’s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety

Bakirtas M., Hindilerden I. Y., Ulu B. U., Ekinci O., Dogu M. H., Aydogdu I., et al.

Indian Journal of Hematology and Blood Transfusion , cilt.42, sa.3, ss.781-791, 2026 (SCI-Expanded, Scopus)

3. mRNA engineering of allogeneic mesenchymal stem cells enables coordinated delivery of T cell engagers and immunotherapeutic cues

Stewart C. A., Daniel S., Curvino E. J., Zhang Y., Kamboh H., Sergueev K., et al.

Nature Biomedical Engineering , cilt.10, sa.4, ss.647-659, 2026 (SCI-Expanded, Scopus)

4. Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era

Seçilmiş S., Aslan Candır B., Hatipoğlu U., Seyhan M., Uncu Ulu B., YİĞENOĞLU T. N., et al.

Pharmaceuticals , cilt.19, sa.4, 2026 (SCI-Expanded, Scopus)

5. Real-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from Turkey

Bakırtaş M., BERBER İ., Hindilerden İ. Y., Dal M. S., İzmir Güner Ş., Uysal A., et al.

Journal of Clinical Medicine , cilt.15, sa.5, 2026 (SCI-Expanded, Scopus)

6. Cladribine Treatment Outcomes in Hairy Cell Leukemia: A Single-center Experience

Seçilmiş S., Candır B. A., Yaman S., Bozan E., Ulu B. U., YİĞENOĞLU T. N., et al.

Acta Haematologica Oncologica Turcica , cilt.58, sa.3, ss.212-217, 2025 (Scopus, TRDizin)

7. Characteristics and Outcomes of Patients with Acute Promyelocytic Leukemia: A Single-center Experience

Seçilmiş S., Candır B. A., Bozan E., Yaman S., Ulu B. U., YİĞENOĞLU T. N., et al.

Acta Haematologica Oncologica Turcica , cilt.58, sa.2, ss.143-149, 2025 (Scopus, TRDizin)

8. Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias

Karakus A., TOPTAŞ T., DAL M. S., Durdu A., Hatipoglu U., Kayer M. A., et al.

Bone Marrow Transplantation , cilt.60, sa.6, ss.864-872, 2025 (SCI-Expanded, Scopus)

9. Are mesenchymal stem cells still effective in acute GvHD management?

Ulu B. U., Hindilerden I. Y., YİĞENOĞLU T. N., Tiryaki T. O., ERKURT M. A., Korkmaz G., et al.

Transfusion and Apheresis Science , cilt.64, sa.1, 2025 (SCI-Expanded, Scopus)

10. Is there a relationship between vitamin D levels and graft versus host disease?

YİĞENOĞLU T. N., Ulu B. U., NAMDAROĞLU S., ERKURT M. A., Sahin R., Okumus N., et al.

Transfusion and Apheresis Science , cilt.64, sa.1, 2025 (SCI-Expanded, Scopus)

11. What should be the optimal dose of post-transplantation cyclophosphamide for GVHD prophylaxis in allogeneic stem cell transplantation?

Ulas T., NAMDAROĞLU S., Hindilerden I. Y., ERKURT M. A., Erer K., YİĞENOĞLU T. N., et al.

Transfusion and Apheresis Science , cilt.64, sa.1, 2025 (SCI-Expanded, Scopus)

12. What is the role of alpha-1 antitrypsin in the management of acute graft versus host disease?

YİĞENOĞLU T. N., ERKURT M. A., DAĞDAŞ S., Ulu B. U., KUKU İ., Durdu A., et al.

Transfusion and Apheresis Science , cilt.64, sa.1, 2025 (SCI-Expanded, Scopus)

13. Twice or once a day? Filgrastim dosing schedule for peripheral hematopoietic stem cells mobilization

Bakırtaş M., Ulu B. U., YİĞENOĞLU T. N., BAŞCI S., Kılınç A., Darçın T., et al.

Hematology, Transfusion and Cell Therapy , cilt.47, sa.1, 2025 (ESCI, Scopus)

14. Role of WT1 in Measurable Residual Disease Follow-Up in the Post Allogeneic Stem Cell Transplant Setting

NAMDAROĞLU S., BAŞCI S., Aslan Candır B., Yaman S., YİĞENOĞLU T. N., Bahsi T., et al.

Journal of Clinical Medicine , cilt.13, sa.17, 2024 (SCI-Expanded, Scopus)

15. Is an earlier strategy for harvesting peripheral blood stem cells in healthy allogeneic donors feasible?

Yaman S., Bozan E., Seçilmiş S., Candır B. A., Kılınç A., BAŞCI S., et al.

Transfusion and Apheresis Science , cilt.63, sa.4, 2024 (SCI-Expanded, Scopus)

16. Is Ruxolitinib an Effective and Safe Therapy for Chronic Myeloproliferative Diseases? Ruksolitinib Kronik Miyeloproliferatif Hastalık için Etkili ve Güvenli Bir Tedavi mi?

Candır B. A., Seçilmiş S., Bozan E., Yaman S., YİĞENOĞLU T. N., KIZIL ÇAKAR M., et al.

Acta Haematologica Oncologica Turcica , cilt.57, sa.1, ss.1-7, 2024 (Scopus, TRDizin)

17. Is neutropenic fever an obstacle to effective stem cell harvesting?

BAŞCI S., Bozan E., Yaman S., Ulu B. U., Bakırtaş M., YİĞENOĞLU T. N., et al.

Asian Journal of Transfusion Science , cilt.18, sa.1, ss.21-26, 2024 (ESCI, Scopus)

18. An effective treatment in Erdheim Chester disease: vemurafenib: a case report

Bozan E., Darçın T., Yaman S., YİĞENOĞLU T. N., KIZIL ÇAKAR M., DAL M. S., et al.

Journal of Medical Case Reports , cilt.17, sa.1, 2023 (ESCI, Scopus)

19. International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report

Özatlı D., Giden A. O., ERKURT M. A., KORKMAZ S., BAŞCI S., Ulas T., et al.

Transfusion and Apheresis Science , cilt.62, sa.2, 2023 (SCI-Expanded, Scopus)

20. Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities

Aslan Candır B., YİĞENOĞLU T. N., KIZIL ÇAKAR M., DAL M. S., ALTUNTAŞ F.

Journal of Oncology Pharmacy Practice , cilt.28, sa.4, ss.972-974, 2022 (SCI-Expanded, Scopus)

21. Could blood groups have prognostic significance on survival in patients with diffuse large B cell lymphoma?

Ulu B. U., BAŞCI S., Bakırtaş M., YİĞENOĞLU T. N., BATGİ H., YILDIZ J., et al.

Leukemia Research , cilt.115, 2022 (SCI-Expanded, Scopus)

22. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies

Yaman S., BAŞCI S., Turan G., Ulu B. U., YİĞENOĞLU T. N., DAL M. S., et al.

Clinical Lymphoma, Myeloma and Leukemia , cilt.22, sa.2, 2022 (SCI-Expanded, Scopus)

23. Pregnancy outcomes in female cancer survivors after hematopoietic stem cell transplantation

İSKENDER D., Ibanoǧlu M., Seçilmiş S., Baysal N., KIZIL ÇAKAR M., Dal M., et al.

European Review for Medical and Pharmacological Sciences , cilt.26, sa.3, ss.996-1003, 2022 (SCI-Expanded, Scopus)

24. Febrile neutropenia risk factors in actively treated diffuse large B-cell lymphoma patients

Bakirtas M., YİĞENOĞLU T. N., BAŞCI S., Ulu B. U., Yaman S., KIZIL ÇAKAR M., et al.

Iraqi Journal of Hematology , cilt.11, sa.1, ss.7-12, 2022 (Scopus)

25. Face masks and polycythemia is the standard hemoglobin cutoff valid in the pandemic?

Yaman S., BAŞCI S., Turan G., Ulu B. U., YİĞENOĞLU T. N., Bahsi T., et al.

Iraqi Journal of Hematology , cilt.11, sa.2, ss.130-133, 2022 (Scopus)

26. Efficiency of intravenous iron carboxymaltose in patients with iron-deficiency anemia due to heavy menstrual bleeding: a single-center experience

Seçilmiş S., İSKENDER D., Candir B., Bozan E., Yaman S., Ulu B., et al.

European Review for Medical and Pharmacological Sciences , cilt.26, sa.10, ss.3487-3492, 2022 (SCI-Expanded, Scopus)

27. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients

Uncu Ulu B., DAL M. S., Yönal Hindilerden İ., Akay O. M., MEHTAP Ö., BÜYÜKKURT N., et al.

Journal of Chemotherapy , cilt.34, sa.3, ss.190-198, 2022 (SCI-Expanded, Scopus)

28. Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers

BAŞCI S., ATA N., ALTUNTAŞ F., YİĞENOĞLU T. N., DAL M. S., KORKMAZ S., et al.

Internal and Emergency Medicine , cilt.17, sa.1, ss.135-139, 2022 (SCI-Expanded, Scopus)

29. Does myeloma genetic have an effect on stem cell mobilization?

BAŞCI S., YİĞENOĞLU T. N., Yaman S., Bozan E., Ulu B. U., Bakırtaş M., et al.

Transfusion and Apheresis Science , cilt.60, sa.6, 2021 (SCI-Expanded, Scopus)

30. Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients

YİĞENOĞLU T. N., BAŞCI S., Şahin D., Ulaş T., DAL M. S., KORKMAZ S., et al.

Transfusion and Apheresis Science , cilt.60, sa.6, 2021 (SCI-Expanded, Scopus)

31. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with relapsed or refractory germ cell tumors

YILDIZ J., Ulu B. U., YİĞENOĞLU T. N., BAŞCI S., Bakirtas M., Sahin D., et al.

Journal of B.U.ON. , cilt.26, sa.6, ss.2531-2536, 2021 (SCI-Expanded, Scopus)

32. Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma

Ulu B. U., YİĞENOĞLU T. N., BAŞCI S., Bakırtaş M., Şahin D., Darçın T., et al.

Leukemia Research , cilt.110, 2021 (SCI-Expanded, Scopus)

33. Molecular evaluation of mutations in acute myeloid leukemia patients from Turkey: A single-center study

Merdin A., DAL M. S., KIZIL ÇAKAR M., Bahsi T., Düzkale N., YILDIZ J., et al.

Medicine (United States) , cilt.100, sa.41, 2021 (SCI-Expanded, Scopus)

34. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study

Akay O. M., Ozbalak M., Pehlivan M., Yildiz B., UZAY A., YİĞENOĞLU T. N., et al.

Hematological Oncology , cilt.39, sa.4, ss.498-505, 2021 (SCI-Expanded, Scopus)

35. The outcome of diffuse large B cell lymphoma patients in adolescent and young adult age group

BAŞCI S., Bakırtaş M., YİĞENOĞLU T. N., Ulu B. U., BATGİ H., YILDIZ J., et al.

Journal of Adolescent and Young Adult Oncology , cilt.10, sa.4, ss.483-487, 2021 (SCI-Expanded, Scopus)

36. Recovery of Symmetrical Peripheral Gangrene of Limbs in a Patient After Performing Hemoadsorption in Septic Shock

Uncu Ulu B., YİĞENOĞLU T. N., Hacıbekiroğlu T., Sağlam D. A., Kılınç A., İSKENDER G., et al.

Journal of Clinical Apheresis , cilt.36, sa.4, ss.649-653, 2021 (SCI-Expanded, Scopus)

37. COVID-19 in hematopoietic cell transplant recipients

ALTUNTAŞ F., ATA N., YİĞENOĞLU T. N., BAŞCI S., DAL M. S., KORKMAZ S., et al.

Bone Marrow Transplantation , cilt.56, sa.4, ss.952-955, 2021 (SCI-Expanded, Scopus)

38. The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor?

BAŞCI S., YİĞENOĞLU T. N., Bakırtaş M., Uncu Ulu B., Yaman S., DAL M. S., et al.

Leukemia Research , cilt.102, 2021 (SCI-Expanded, Scopus)

39. Old is bad? The effect of age on peripheral stem cell mobilization and transplantation outcomes

BAŞCI S., Bakırtaş M., Uncu Ulu B., YİĞENOĞLU T. N., Yaman S., BATGİ H., et al.

Transfusion and Apheresis Science , cilt.60, sa.1, 2021 (SCI-Expanded, Scopus)

40. Convalescent plasma therapy in patients with COVID-19

ALTUNTAŞ F., YİĞENOĞLU T. N., BAŞCI S., DAL M. S., KORKMAZ S., Turgut B., et al.

Transfusion and Apheresis Science , cilt.60, sa.1, 2021 (SCI-Expanded, Scopus)

41. Is classical Hodgkin lymphoma a different disease in the elderly? A single-center retrospective cohort study

YILDIZ J., Ulu B., YİĞENOĞLU T. N., BAŞCI S., Darçin T., Bakirtaş M., et al.

European Review for Medical and Pharmacological Sciences , cilt.25, sa.10, ss.3655-3660, 2021 (SCI-Expanded, Scopus)

42. Demonstration of SARS-CoV-2 in bone marrow cells and changes in the hematopoietic cell lines

Hacibekiroǧlu T., Kalpakci Y., YİĞENOĞLU T. N., İŞsever K., Trak G., Hacibekiroǧlu İ., et al.

Acta Medica Mediterranea , cilt.37, sa.2, ss.1217-1222, 2021 (SCI-Expanded, Scopus)

43. COVID-19 clinical course and blood groups: Turkish population-based study

Dal M. S., ATA N., ALTUNTAŞ F., BAŞCI S., YİĞENOĞLU T. N., KORKMAZ S., et al.

Turkish Journal of Medical Sciences , cilt.51, sa.4, ss.1659-1664, 2021 (SCI-Expanded, Scopus, TRDizin)

44. The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience

BATGİ H., Merdin A., DAL M. S., KIZIL ÇAKAR M., YILDIZ J., BAŞCI S., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.8, ss.1857-1863, 2020 (SCI-Expanded, Scopus)

45. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

BAŞCI S., ATA N., ALTUNTAŞ F., YİĞENOĞLU T. N., DAL M. S., KORKMAZ S., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.7, ss.1676-1682, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

46. A multiple myeloma patient who developed ischemic colitis during lenalidomide treatment: A rare case report

BATGİ H., DAL M. S., Merdin A., KIZIL ÇAKAR M., YİĞENOĞLU T. N., ALTUNTAŞ F.

Journal of Oncology Pharmacy Practice , cilt.26, sa.6, ss.1499-1500, 2020 (SCI-Expanded, Scopus)

47. Evaluation of Risk Factors for Mortality in Febrile Neutropenia

ÇEKEN S., GEDİK H., İSKENDER G., Demirelli M., MERT D., Toros G. Y., et al.

Journal of Infection in Developing Countries , cilt.14, sa.8, ss.886-892, 2020 (SCI-Expanded, Scopus)

48. Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption

YİĞENOĞLU T. N., Ulas T., DAL M. S., KORKMAZ S., ERKURT M. A., ALTUNTAŞ F.

Transfusion and Apheresis Science , cilt.59, sa.4, 2020 (SCI-Expanded, Scopus)

49. Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor

Merdin A., KIZIL ÇAKAR M., DAL M. S., MERT D., YILDIZ J., BAŞCI S., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.4, ss.929-932, 2020 (SCI-Expanded, Scopus)

50. Inferior prognosis in poor mobilizing myeloma patients

YİĞENOĞLU T. N., BAŞCI S., Ulu B. U., Bakırtaş M., Kılınç A., Şahin D., et al.

Transfusion and Apheresis Science , cilt.59, sa.3, 2020 (SCI-Expanded, Scopus)

51. The effect of serum vitamin B12, folate, ferritin levels and transferrin saturation on stem cell mobilization in allogeneic donors

YİĞENOĞLU T. N., BAŞCI S., Bakırtaş M., Ulu B. U., Kılınç A., Şahin D., et al.

Transfusion and Apheresis Science , cilt.59, sa.3, 2020 (SCI-Expanded, Scopus)

52. The effect of high-dose cytarabine followed by autologous hematopoietic stem cell transplantation on the outcome of patients with mantle cell lymphoma

KIZIL ÇAKAR M., Tekgündüz E., Dal M. S., Merdin A., BAŞCI S., Uğur B., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.2, ss.273-278, 2020 (SCI-Expanded, Scopus)

53. Analysis of pre-chemotherapy WBC, PLT, monocyte, hemoglobin, and MPV levels in acute myeloid leukemia patients with WT1, FLT3, or NPM gene mutations

Merdin A., DAL M. S., KIZIL ÇAKAR M., YILDIZ J., Ulu B. U., BATGİ H., et al.

Medicine (United States) , cilt.99, sa.14, 2020 (SCI-Expanded, Scopus)

54. The Outcome of Autologous Stem Cell Transplantation in Adolescent and Young Adult Patients with Multiple Myeloma

YİĞENOĞLU T. N., BAŞCI S., Ulu B. U., Bakirtas M., Sahin D., Darcin T., et al.

Eurasian Journal of Medicine and Oncology , cilt.4, sa.1, ss.79-83, 2020 (ESCI, Scopus, TRDizin)

55. Evaluation of clinical outcome and mixed chimerism follow-up after allogeneic hematopoietic stem cell transplantation in hematological malignancies

Bahsi T., YİĞENOĞLU T. N., ERDEM H. B., KIZIL ÇAKAR M., DAL M. S., ALTUNTAŞ F.

Gazi Medical Journal , cilt.31, sa.1, ss.52-55, 2020 (ESCI, Scopus)

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Atıf (TrDizin)

H-İndeks (TrDizin)

Atıf (Diğer Toplam)

Proje

Tez Danışmanlığı

Açık Erişim